Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma
Corresponding Author
James T. May MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Corresponding author: J. T. May, Arkansas Otolaryngology Center, Little Rock, Arkansas. E-mail: [email protected]Search for more papers by this authorNikhil Rao MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorRoberto D. Sabater MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorHinda Boutrid MS
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJimmy J. Caudell MD, PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorFaisal Merchant MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorGang Han PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorTapan A. Padhya MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJudith C. McCaffrey MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorTawee Tanvetyanon MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorRonald Deconti MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJulie Kish MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorThomas V. McCaffrey MD, PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorAndy Trotti MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorCorresponding Author
James T. May MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Corresponding author: J. T. May, Arkansas Otolaryngology Center, Little Rock, Arkansas. E-mail: [email protected]Search for more papers by this authorNikhil Rao MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorRoberto D. Sabater MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorHinda Boutrid MS
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJimmy J. Caudell MD, PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorFaisal Merchant MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorGang Han PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorTapan A. Padhya MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJudith C. McCaffrey MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorTawee Tanvetyanon MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorRonald Deconti MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorJulie Kish MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorThomas V. McCaffrey MD, PhD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorAndy Trotti MD
Head and Neck Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Search for more papers by this authorThese data were previously presented in poster format at the 93rd Annual American Radium Society Meeting in Palm Beach, FL, April 30–May 4, 2011.
Abstract
Background
Over the past decade, intensity-modulated radiation therapy (IMRT) has gained widespread use in the treatment of head and neck cancer.
Methods
All patients with squamous cell carcinoma of the oropharynx treated with primary IMRT with or without chemotherapy over a 5-year period were reviewed. Outcomes and morbidity were analyzed and compared with previously published data.
Results
In all, 170 patients were included in the analysis. The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 92%, 91%, 80%, and 87%, respectively. Feeding tubes were present in 55% of patients during treatment, but remained in only 1% 2 years following treatment.
Conclusions
This study confirms that IMRT yields excellent treatment outcomes for oropharyngeal carcinoma. Although acute toxicity remains a problem, late toxicity rates are low and long-term feeding tube dependence is rare compared with conventional radiation therapy. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1796–1800, 2013
REFERENCES
- 1Vikram B.Changing patterns of failure in advanced head and neck cancer.Arch Otolaryngol1984; 110: 564–565.
- 2Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Werning JW, Villaret DB.Definitive radiotherapy for squamous cell carcinoma of the base of tongue.Am J Clin Oncol2006; 29: 32–39.
- 3Mendenhall WM, Morris CG, Amdur RJ, et al.Definitive radiotherapy for tonsillar squamous cell carcinoma.Am J Clin Oncol2006; 29: 290–297.
- 4Chao KS, Deasy JO, Markman J, et al.A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.Int J Radiat Oncol Biol Phys2001; 49: 907–916.
- 5Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA.Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.Int J Radiat Oncol Biol Phys2001; 50: 695–704.
- 6 FL Greene, DL Page, ID Fleming, et al., editors. AJCC Cancer Staging Manual, 6th edition).New York:Springer-Verlag;2002.
- 7 Common Toxicity Criteria Version 2.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4–30-992.pdf. Accessed September 15,2011.
- 8 RTOG/EORTC Late Radiation Morbidity Scoring Schema. http://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx. Accessed September 15,2011.
- 9Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C.Effect of radiation techniques in treatment of oropharynx cancer.Laryngoscope2008; 118: 635–639.
- 10Lee NY, de Arruda FF, Puri DR, et al.A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.Int J Radiat Oncol Biol Phys2006; 66: 966–974.
- 11Daly ME, Le QT, Maxim PG, et al.Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure.Int J Radiat Oncol Biol Phys2010; 76: 1339–1346.
- 12Garden AS, Morrison WH, Wong PF, et al.Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma.Int J Radiat Oncol Biol Phys2007; 67: 438–444.
- 13Huang K, Xia P, Chuang C, et al.Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma.Cancer2008; 113: 497–507.
- 14Sanguineti G, Gunn GB, Endres EJ, Chaljub G, Cheruvu P, Parker B.Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma.Int J Radiat Oncol Biol Phys2008; 72: 737–746.
- 15Shoushtari A, Meeneghan M, Sheng K, et al.Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status.Cancer2010; 116: 2645–2654.
- 16Setton J, Caria N, Romanyshyn J, et al.Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.Int J Radiat Oncol Biol Phys2012; 82: 291–298.
- 17Feng FY, Kim HM, Lyden TH, et al.Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.J Clin Oncol2010; 28: 2732–2738.
- 18Saba NF, Edelman S, Tighiouart M, et al.Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis.Head Neck2009; 31: 1447–1455.
- 19Yao M, Nguyen T, Buatti JM, et al.Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research.Am J Clin Oncol2006; 29: 606–612.
- 20Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM, Li JG.Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma.Laryngoscope2010; 120: 2218–2222.
- 21Chaturvedi AK, Engels EA, Anderson WF, Gillison ML.Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.J Clin Oncol2008; 26: 612–619.
- 22Ang KK, Harris J, Wheeler R, et al.Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med2010; 363: 24–35.
- 23Nichols AC, Faquin WC, Westra WH, et al.HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma.Otolaryngol Head Neck Surg2009; 140: 228–234.
- 24Ragin CC, Taioli E.Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.Int J Cancer2007; 121: 1813–1820.
- 25Harrison LB, Zelefsky MJ, Pfister DG, et al.Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue.Head Neck1997; 19: 169–175.
10.1002/(SICI)1097-0347(199705)19:3<169::AID-HED1>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- 26Jensen AB, Hansen O, Jorgensen K, Bastholt L.Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer.Acta Oncol1994; 33: 487–491.
- 27Bjordal K, Kaasa S, Mastekaasa A.Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy.Int J Radiat Oncol Biol Phys1994; 28: 847–856.
- 28Nutting CM, Morden JP, Harrington KJ, et al.Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.Lancet Oncol2011; 12: 127–136.
Citing Literature
